Patents by Inventor Matthias Lingemann

Matthias Lingemann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240226118
    Abstract: Embodiments of a method for inhibiting viral infection in a subject are provided herein. In some embodiments, the method comprises administration of a competitive antagonist of ouabain binding to ATP1A1 to inhibit respiratory syncytial virus infection in the subject.
    Type: Application
    Filed: December 13, 2023
    Publication date: July 11, 2024
    Applicant: The U.S.A., as represented by the Secretary, Department of Health and Human Services
    Inventors: Peter L. Collins, Matthias Lingemann, Shirin Munir
  • Publication number: 20220249518
    Abstract: Embodiments of a method for inhibiting viral infection in a subject are provided herein. In some embodiments, the method comprises administration of a competitive antagonist of ouabain binding to ATP1A1 to inhibit respiratory syncytial virus infection in the subject.
    Type: Application
    Filed: April 20, 2022
    Publication date: August 11, 2022
    Applicant: The U.S.A., as represented by the Secretary, Department of Health and Human Services
    Inventors: Peter L. Collins, Matthias Lingemann, Shirin Munir
  • Patent number: 11337988
    Abstract: Embodiments of a method for inhibiting viral infection in a subject are provided herein. In some embodiments, the method comprises administration of a competitive antagonist of ouabain binding to ATP1A1 to inhibit respiratory syncytial virus infection in the subject.
    Type: Grant
    Filed: September 26, 2019
    Date of Patent: May 24, 2022
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Peter Collins, Matthias Lingemann, Shirin Munir
  • Publication number: 20200101086
    Abstract: Embodiments of a method for inhibiting viral infection in a subject are provided herein. In some embodiments, the method comprises administration of a competitive antagonist of ouabain binding to ATP1A1 to inhibit respiratory syncytial virus infection in the subject.
    Type: Application
    Filed: September 26, 2019
    Publication date: April 2, 2020
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Servic
    Inventors: Peter Collins, Matthias Lingemann, Shirin Munir